Tag Archives: Michael A. Caligiuri
By John Seffrin and Michael Caligiuri
An excerpt of an op-ed by John R. Seffrin, PhD, CEO of the American Cancer Society Cancer Action Network and Research!America Board member, and Michael A. Caligiuri, MD, director of the Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute published in U.S News & World Report.
Clinical trials are often a patient’s only viable treatment option for surviving cancer – a disease that kills 1,500 people every day in this country. But haphazard federal budget cuts, a consequence of the so-called “sequester” that was initiated in March, threaten to stall or eliminate critical clinical trials nationwide and further threaten important basic laboratory research. For the one in two men and one in three women in America who will hear those three most dreaded words, “You have cancer,” in their lifetime, research provides more than the promise of new treatments and therapies; it offers hope for beating a disease that was once considered a virtual death sentence.
The Ohio State University’s Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute conducts groundbreaking clinical trials for cancer research. Due to mandated federal budget cuts earlier this year, the National Cancer Institute was already forced to reduce by half the number of participants in clinical trials at OSU. Under sequestration, these trials will likely be completely eliminated this year, affecting patients undergoing treatment for leukemia, lymphoma, breast cancer and a variety of other forms of cancer. Continue reading →